Maximus
, Inc.
MMS
has an impressive
Growth Score
of A. This style score condenses all the essential metrics from a company’s financial statements to get a true sense of the quality and sustainability of its growth. The company’s revenues for fiscal 2022 are expected to improve 5.7% year over year.
Factors That Auger Well
With more than 40 years of experience, Maximus has grown to be a leading operator of government health and human services programs globally. The company’s business process management expertise and its ability to deliver cost-effective, efficient and high-scale solutions position it as a lucrative partner to governments.
Maximus maintains solid relationships and a strong reputation with governments. Its long-term contracts provide the company with predictable recurring revenue streams. The company continuously seeks long-term relationships with clients in not only those markets where they operate, but also in adjacent ones. MMS is also focused on expanding its foothold in clinical services, as well as in long-term services and supports. Moreover, complex health needs have increased the requirement for government social benefits and safety-net programs. This should continue driving demand for the company’s services.
The 2021 buyout of Attain has strengthened two core pillars of Maximus’ long-term corporate strategy, including accelerating digital transformation and the ongoing expansion into the U.S. federal market.
Some Risks
Maximus’ current ratio at the end of March quarter was pegged at 1.45, lower than the current ratio of 1.57 reported at the end of the prior-year quarter. Decreasing current ratio is not desirable as it indicates that the company may have problems meeting its short-term obligations.
Zacks Rank and Stocks to Consider
Maximus currently carries a Zacks Rank #3 (Hold).
Investors interested in the broader Zacks
Business Services
sector can consider stocks like
Avis Budget Group, Inc.
CAR
,
Genpact Limited
G
and
CRA International, Inc.
CRAI
.
Avis Budget sports a Zacks Rank #1 (Strong Buy) at present. CAR has a long-term earnings growth expectation of 19.4%.You can see
the complete list of today’s Zacks #1 Rank stocks here
.
Avis Budget delivered a trailing four-quarter earnings surprise of 102%, on average.
Genpact carries a Zacks Rank of 2 (Buy) at present. G has a long-term earnings growth expectation of 12.3%.
Genpact delivered a trailing four-quarter earnings surprise of 13.3%, on average.
CRA International also carries a Zacks Rank #2 currently. CRAI has a long-term earnings growth expectation of 14.3%.
CRAI delivered a trailing four-quarter earnings surprise of 35.8%, on average.
Zacks Names “Single Best Pick to Double”
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report